The Northern New England Clinical Oncology Society embarked on a study to assess whether there was a disparity in cancer care delivered in rural and urban areas of New Hampshire, Maine, and Vermont. The work undertaken here was to extend the findings initiated by the Maine cancer consortium. Clinical indicators of cancer care served as surrogate markers to look for discrepancies in care delivered in rural areas when compared to urban areas in colon and breast cancer patients. The three respective state cancer coalitions, registrars, hospitals, physicians, epidemiologists, and statisticians developed a working group that shared resources, streamlined data access, and developed uniform definitions so that almost 9000 patient records in 79 separate institutions could be closely evaluated. The ability to access data in such a large geographical area enabled a statistically valid comparison that would not be possible if it were confined to one state. The goal was to take a snapshot of cancer care delivered in Northern New England (NNE) during 2003 and 2004. Evaluation of differences in care offered in rural areas could be assessed to identify needs and barriers that could be addressed.
Executive Summary
The Northern New England Clinical Oncology Society embarked on a study to assess whether there was a disparity in cancer care delivered in rural and urban areas of New Hampshire, Maine, and Vermont. The work undertaken here was to extend the findings initiated by the Maine cancer consortium. Clinical indicators of cancer care served as surrogate markers to look for discrepancies in care delivered in rural areas when compared to urban areas in colon and breast cancer patients. The three respective state cancer coalitions, registrars, hospitals, physicians, epidemiologists, and statisticians developed a working group that shared resources, streamlined data access, and developed uniform definitions so that almost 9000 patient records in 79 separate institutions could be closely evaluated. The ability to access data in such a large geographical area enabled a statistically valid comparison that would not be possible if it were confined to one state. The goal was to take a snapshot of cancer care delivered in Northern New England (NNE) during 2003 and 2004 . Evaluation of differences in care offered in rural areas could be assessed to identify needs and barriers that could be addressed.
The results showed several interesting findings. Breast cancer patients in urban communities were diagnosed more often with non-invasive breast cancer than patients living in rural areas. This important finding may have several explanations including access and availability to screening, or ability to obtain or interpret biopsies in rural areas. Further studies will need to clarify this finding. Moreover, breast cancer patients in urban areas also had more sentinel lymph node (SLN) procedures than their rural counterparts. The SLN procedure was diffusing into the community from major teaching institutions in NNE and replacing the previous standard of regional lymph node dissection during this time. The ability to capture community acceptance/expertise of a new therapy, i.e. SLN, over time is also an important finding. It would be interesting to see how rapidly this (and other) new technologies are accepted and utilized in the rural community setting. Breast cancer patients undergoing SLN also received more post lumpectomy radiation therapy (RT) than patients who did not receive SLN. Even though no geographical variation between rural and urban areas was discerned, it would suggest that patients with access to a new technology also had easier access to RT. Defining variations in access to care therefore may be better measured if we looked at the difficulty patients may have in getting to the institutions where the care is delivered (i.e. driving times). The same issue was found to be true in colon cancer patients. Post operative chemotherapy is usually recommended in patients with Stage III colon cancer. A significantly higher proportion of patients received this adjuvant chemotherapy in urban rather than rural areas. The significance of these findings will require further testing and evaluation.
One difficulty the working group faced was the retrospective collection of data and callbacks. The study captured one point in time and it would be important to capture these surrogate markers (or other relevant data) again to assess whether access to care in NNE is getting better or worse. Continuing to do this work prospectively will enable us to collect data in a scientifically valid and instructive way, and hopefully would give us an ongoing tool to clarify some of the issues noted here and find strengths and weakness in the fragile care network now in place. The map shown on page 8 illustrates accessible points into the system. Are these sufficient? Do we need more resources? Where? The answer to these questions will be critical if we hope to cure more patients with cancer. The development of new technology and therapy will not save lives if patients do not have access to them. The future will only improve if important tools to measure how we do over time are developed and that is and continues to be the major goal of this study. Before we can break down barriers to care we have to see if and where they exist. Cooperation by the large collaborative group of the three respective states enabled the working group to define a common methodology to collect aggregate data for comparison. Several operational differences among the three states' cancer registries were overcome in order to obtain a standardized and accurate data set. The Rural and Urban Residence Commuting Area (RUCA) classification scheme was utilized to classify residence into three types -small rural, large rural, and urban areas.
A total of 6,134 women with breast cancer were evaluated. A higher percentage of younger women (<50 years old) were diagnosed in urban areas (27.4%) than large rural areas (22.3%) or small rural areas (20.4%). More non invasive breast cancer was diagnosed in urban areas as well, but no associated increase in early Stage I breast cancer was seen in urban areas. Breast conserving surgery was performed in similar proportions in rural and urban areas, but sentinel lymph node (SLN) dissection was more common in urban areas (44.1%) than large rural (39.8%) and small rural areas (37.8%). A positive correlation between SLN dissection and post lumpectomy radiation therapy was seen. SLN patients received radiation therapy more frequently after lumpectomy than patients who underwent regional lymph node dissections without SLN (85.9% versus 75.5%). However, the rates of post lumpectomy radiation therapy in small and large rural (70.9% and 73.9% respectively) versus urban areas (72.2%) showed no significant difference. Thus, the explanation for the higher use of radiation therapy in post lumpectomy patients undergoing some form of SLN procedure is not explained by geographical differences in this study.
Colon cancer patients evaluated in the three residential classifications also showed consistencies in certain characteristics. No significant difference was noted in the distribution of stage (Stage 0,I,II,III,IV) at presentation between rural and urban areas. Similar to the results from breast cancer, patients with early Stage I colon cancer were diagnosed at a similar frequency in small rural areas (26.0%) as in urban areas (23.2%). The delivery of adjuvant therapy in Stage III colon cancer was less frequent in rural areas (57.3%) when compared to urban areas (64.7%) in this study, and this finding was statistically significant.
The ability for a patient to access care in rural areas may be limited both by patient and network/provider considerations. Providing adequate care in rural areas requires coordinated planning and resource management to limit barriers to care in cancer patients. State boundaries do not serve as an isolated barrier but differences in population density and commuting distances may play a significant role. This study illustrated areas where data were comparable in rural and urban areas of northern New England, such as the use of breast conserving surgery, proportion of positive nodes and stage at presentation for breast and colon cancer, and the utilization of post lumpectomy radiation therapy. The study did reveal differences in care offered to urban patients versus rural patients. Breast cancer patients in urban northern New England presented at a younger age and with a higher proportion of Stage 0 (i.e. non invasive disease). Colon cancer patients with Stage III disease proportionally received adjuvant chemotherapy less often in rural areas as opposed to their urban counterparts.
These differences may or may not result in overall survival differences but do point out that there are significant differences in care between rural and urban areas that should be studied further. If these disparities increase, or the fragile network in place is disrupted, then we would expect to see more glaring discrepancies than those noted here.
We hope the state cancer partnerships in northern New England will use these data to plan, implement, and evaluate activities that are targeted toward improving access to high quality oncologic care.
Introduction
The Northern New England Clinical Oncology Society (NNECOS) membership includes community and academic oncologists, oncology nurses, mid-level practitioners and practice managers. NNECOS' mission is to assure the availability of and access to high quality oncology care in the region.
The northern New England area of Vermont, Maine, and New Hampshire has both rural and urban areas covering a geographic area comparable to the State of New York. There are 79 hospitals in the region. Oncology services are provided in hospital based oncology practices, three large private oncology practices, two large teaching institutions, and their respective satellite clinics. These services are supplemented by 18 radiation therapy units, including hospital-based and outpatient facilities, which are illustrated in Figure 1 . 3. Determine the percentage of breast cancer patients who undergo sentinel lymph node dissection (SNL) and identify the percentage of women who receive postlumpectomy radiation therapy.
A collaboration of this size and complexity requires support at the local, state, and national levels. Over the course of the year, the project team expanded to include medical and radiation oncologists, surgeons, representatives from the state departments of health, cancer registries at the state and local level, comprehensive cancer control programs, statewide cancer care consortiums, medical centers, the American Cancer Society and the National Cancer Institute.
The Centers for Disease Control and Prevention (CDC) has been committed to state cancer planning as a mechanism to promote comprehensive cancer control. Comprehensive cancer control is defined as a collaborative process through which a community and its partners pool resources and align specific tactics to promote prevention and early detection, expand access to quality cancer care services and enhance cancer survivorship. The CDC supports cancer surveillance through the National Program for Cancer Registries (NPCR). State cancer registry data are used to monitor and target cancer control activities related to access to care.
The Treatment Work Group of the Maine Cancer Consortium has previously assessed concordance with national cancer treatment guidelines for breast and colon cancer. The Consortium has used the findings to understand where adherence to clinical benchmarks could be improved. The three-state collaboration provides the opportunity to build upon Maine's analysis and investigate rural/urban differences in access to care.
The state cancer plans of Maine, New Hampshire and Vermont have strong similarities relating to their goals of assessing access to quality care, and they include specific strategies to utilize state cancer registry data to evaluate quality of care issues in the diagnosis, staging and disease management.
The Cancer Registrars Association of New England (CRANE) held their annual conference in October, 2008, in Burlington, Vermont. Because registry personnel from the tri-state area were all in one location, the project team felt this was an opportunity to garner the needed support of the registry staff; therefore, all registrars in the tri-state area were invited to a special dinner meeting. The project leader and other members of the project team presented the study to the approximately 20 registrars in attendance and requested their assistance in ensuring that high quality study data was available. At the conclusion, the registrars were excited about their role in providing data for a study that could bring about a meaningful change to the oncology care in the region.
Methods

Data Sources
Data were collected by the three central cancer registries of Maine, New Hampshire and Vermont. By law, each state is required to collect cancer incidence data for all cancers diagnosed or treated among residents of the three states. Case completeness for the three registries for diagnosis years 2003 and 2004 was estimated to be 95% or greater. 1 Each central registry identified cases of colon and breast cancer diagnosed during the years 2003 to 2004. The variables of interest for the study were assessed for completeness and optimized by requesting updated or additional data from the reporting facilities. We used demographic data and the residence of each patient at the time of diagnosis. For colon cancer cases, data on the stage at diagnosis and surgical and chemotherapy treatments given within the first 6 months after diagnosis were collected. Similarly, for breast cancer cases, data on the stage at diagnosis, surgical and radiation therapy treatments given within the first 6 months after diagnosis were collected. Information on the use of sentinel lymph node dissection and the use of post-lumpectomy radiation therapy was collected. 
Definition of Rural and Urban Residence
We defined patients' residence using Rural-Urban Commuting Area (RUCA) classification scheme. 2 This classification system creates rural and urban categories at the US Census tract and ZIP code level by considering urbanization, population density, and commuting patterns. A RUCA code was assigned to each individual based on the zip code of their residence and grouped into three recommended categories: urban, large rural town and small rural town (Figure 1) . 
Derivation of Stage
Standard of Care Assumptions
The College of American Pathologists and AJCC recommend a minimum of 12 lymph nodes for adequate staging of colon cancer. For Stage IIB colon cancer, treating with adjuvant chemotherapy is controversial; however, the American Society of Clinical Oncology (ASCO) recommends consideration of adjuvant chemotherapy in a subset of Stage IIB patients, including those that are medically fit, inadequately staged (<12 nodes examined) and those with high risk features (T4 lesions, perforation, poorly differentiated histology). For Stage III colon cancers, surgical resection and adjuvant chemotherapy is recommended. 4, 5 For Stage 0, I, and II breast cancer, the recommended treatment is lumpectomy followed by radiation therapy (RT). The exceptions are patients age 70 or older, small tumor size (<1 cm), estrogen receptor antigen (ERA) positive cases, and patients with contraindications, including early pregnancy, prior radiation, and connective tissue disorders. Also recommended is sentinel lymph node surgery to provide accurate axillary staging. SLN surgery is controversial for Stage 0, but is the standard of care for Stage I and II. 6 
Data Analysis
We analyzed the data using SAS software. The total numbers and percents of cases in each category were tabulated overall by RUCA category then by stage and by treatment. To describe colon cancers by stage and by treatment, we excluded cases with unknown stage and unknown surgical and radiation treatment. To describe breast cancers by stage and by treatment, we excluded lobular carcinoma in situ cases. Breast cancers with unknown stage and unknown surgical and radiation treatment were also excluded. Comparisons were made using chi-squared tests. Where individual cells contained 5 or fewer cases, the case counts were suppressed.
Results
Breast Cancer
Through the three state cancer registries, we identified a total of 6,134 women diagnosed with breast cancer in the study period. For 85.4% of these women, this was a first diagnosis of cancer while 14.6% had a previous diagnosis of cancer. At the time of diagnosis, the mean age was 61 (SD: 13.9), and 87.0% had Stage 0-II disease.
We used chi-squared tests to assess the effect of residence on breast cancer diagnosis and treatment ( Table 1) . There were residence-related differences in the distribution of age categories at diagnosis (p<0.001), with a greater proportion of urban women diagnosed at a younger age. Tumor size at diagnosis also showed differences between rural and urban residents, with a greater proportion of patients living in a small rural area having larger tumors (p=0.006). The distribution of stage at diagnosis (0 through IV) also varied by residence (p<0.001) but without an easily interpretable pattern. In urban areas, proportionately more patients were diagnosed with non invasive breast cancer (Stage 0) than in rural areas, but fewer with Stage I. Combining the totals for Stages 0 and I shows similar proportions across the three residence categories (59.7%, 63.2% and 62.7% for small rural, large rural and urban, respectively). Metastatic disease at presentation was seen in similar proportions in both small rural and urban areas (3.4% versus 3.1%). Overall, 3,808 women (62.1%) underwent lumpectomy (59.7% small rural vs. 63.3% urban), 1,981 (32.3%) had mastectomy while 342 (5.6%) had no surgery. Of the entire cohort, 2,535 (41.3%) had sentinel lymph node sampling alone or with further axillary surgery. While there was no statistically significant difference in use of breast conserving surgery by residence, we observed differences in the use of sentinel lymph node sampling from 44.1% for urban women to 39.9% for women in large rural areas and 37.6% for women in small rural areas, respectively (p<0.001). The proportions of patients with any positive nodes, all negative nodes, or no dissection performed were independent of residence (p=0.206).
Among the 5,591 women who did undergo surgery, we evaluated the frequency of postoperative radiation therapy (RT) stratified by type of surgery ( The use of adjuvant RT after lumpectomy was positively associated with sentinel lymph node sampling (p<0.001). Patients with sentinel lymph node dissections (including the group that had both sentinel lymph node and regional lymph nodes dissected) had a higher rate of post lumpectomy RT utilization -85.9% (1,517 of a total of 1,766 patients), compared to 75.5% (593 of 785 patients) who underwent regional lymph node dissection alone, and 48.0% (523 of 1090 patients) who did not undergo and lymph node sampling.
The use of adjuvant RT was also inversely associated with lymph node involvement (p<0.001). In the 1941 women who underwent mastectomy, there was an inverse association between post-mastectomy radiation therapy and age (p<0.001) and a positive association with tumor size 2cm or greater vs. <2cm (p<0.001), any lymph node dissection performed vs. not performed (p<0.001), nodal involvement vs. all negative (p<0.001) and late stage (III or IV) vs. early stage (0-II) disease (p<0.001). (Table 3) , we observed no differences in adjuvant RT utilization based upon residence (p=0.642) . However, residence was strongly associated with the type of lymph node sampling that was done (p<0.001). 
Colon Cancer
The findings from 2,848 colon cancer patients diagnosed in 2003 and 2004 are illustrated in Table 4 . The age at diagnosis in the four categories was similar in rural and urban areas, both in terms of the mean age at diagnosis (70 years in all groups) and the distribution by age category (p=0.361). Overall, 7.4% of patients were diagnosed before the age of 50 and 42.6% of patients were diagnosed over the age of 75.
Patients who presented with their colon cancer as their first primary represented 82.4% of patients diagnosed, and again there was no statistically significant difference between rural and urban areas (p=0.284). Table 4 shows that the distributions of stage at diagnosis (Stages 0, I, II, III, and Stage IV) were similar in the three geographic areas studied (p=0.666). Early non invasive disease (Stage 0) was diagnosed in 11.7% of patients and metastatic (Stage IV) disease in 14.5% of cases. Stage I disease was diagnosed in 247 patients (26.0%) in small rural areas and in 309 patients (23.2%) in urban areas. Stage II and III patients represented 24.4% and 21.5% of the total, with similar distributions in the different geographical areas. The histology of the various subgroups studied also did not differ significantly between geographic areas (p=0.805).
The type of surgery performed in small rural, large rural and urban areas was evaluated closely. A comparison of the three geographical areas suggested some differences in treatment with either segmental resection, another form of surgery, or non surgical measures (p<0.001). Local excision rates represented 11.5%, 12.3%, and 11.5% in these areas respectively; segmental resection represented 76.2% of the total procedures performed, lowest in the large rural areas (72.7%) and highest in urban areas (77.2%); and a colectomy was performed in only 2.2% (62 patients).
An important component of surgery is the number of lymph nodes removed at the time of surgery. The standard of removing at least 12 lymph nodes at operation was performed in 1,219 patients, comprising 42.8% of all patients (total including non invasive disease and non surgically treated patients), 46.8% of the 2,607 treated surgically, and 55.3% of the 2,203 surgically-treated patients who had any lymph nodes removed. There was no significant difference among the three geographic areas in the proportions of patients having any lymph node dissection performed (p=0.743); but, among those who had such a dissection (n=2,203), the likelihood of having the standard of 12 or more nodes removed (55.3%) showed borderline significant differences (p=0.079) among small rural (56.0%), large rural (50.6%), or urban (56.9%) areas (as a percentage of patients who had any lymph nodes sampled).
Adjuvant chemotherapy administration is offered to patients with Stage III disease and a subset of high risk Stage II patients. We undertook this study to closely evaluate the 597 patients in this subgroup who had been treated surgically ( Table 5) . Stage III patients in urban areas received adjuvant chemotherapy more often (158 of 244; 64.7%) than those in the small and large rural areas combined; (161 of 281; 57.3%) (p=0.001). Similar proportions received adjuvant chemotherapy in small rural areas (58.3%) and large rural areas (55.8%). Combining Stages IIB and III, there was no significant difference overall in the use of adjuvant chemotherapy between urban (63.4%) and combined rural regions (56.9) (p=0.105).
Limitations
Access to Care
Access to care is complex, encompassing perceptions of access (convenience, satisfaction with services, presence of a provider) as well travel time and travel distance to services. 7 Income, insurance status, and race/ethnicity can also influence a person's access to care. We used a person's zip code at time of diagnosis to categorize residence as urban, large rural, or small rural. Thus, only one aspect of access to care (residence) was considered. Furthermore, this is a proxy for distance from services, since drive time analysis between a person's residence and the treatment center was not computed. We assumed that people living in more urban areas at the time of diagnosis lived closer to services.
At best the concept of rural is complex, multifaceted, and often vague. 8 There can be significant variations in the demographics, economics, culture, and environmental characteristics of different rural places. Large rural towns that are not too distant from urban areas often have more in common with urban areas than they do with small towns. 9 We have used three residential classifications to gain a finer level of detail, and we have combined three states' data to have more power in the analysis. However, there is still a possibility that residence classifications are oversimplified and could erroneously disguise or reveal differences in access to quality oncology care. For example, Dartmouth Hitchcock Medical Center is a tertiary care center located in a large rural town (not an urban area) in New Hampshire.
We are inferring access to care from residence at a point in time because the cancer registries record residence at the time a diagnosis occurred. This may be a poor indicator of current or historic access to care because we do not know the length of time each person lived at his or her residence. People who originally lived in urban areas and were likely to have better access to care, then moved to a rural setting, and were later diagnosed with cancer, would be classified as rural. The converse is also true.
Differences in State Cancer Registration Systems
Although the state cancer registries of Maine, New Hampshire, and Vermont conform to the federal reporting standards of NPCR and the North American Association of Central Cancer Registries (NAACCR), operational differences exist among the registries. For example, each state uses a different software application for its cancer registry database.
Each cancer registry's software application has a slightly different way of creating a consolidated tumor record from multiple abstract records. For example, two states' systems merge the "best" data from abstracts into a single consolidated record at the time of export; one state's system stores a static consolidated record. This created an error in the handling of one treatment data item for one state, which was corrected in the final data set. Other idiosyncrasies like this could exist, which might affect the comparability of data across the three states.
Each state has a different set of data items that it collects from healthcare facilities and providers. For example, Vermont did not require the hormonal status of breast cancer tumors (ERA/PRA) for the diagnosis years studied, but the data were included if healthcare facilities opted to send it to the state.
The approach used to verify zip code for each patient is different in each state; this relates directly to the rural/urban residential classification used for the study. Another limitation is that zip codes can change over time. Nevertheless, the approach of using the ZIP Code RUCA approximation was preferred over other methods involving town of residence due to even more problematic differences in validation and standardization of town names among the three states' registries. We also used zip codes representing PO Boxes where residential addresses were unavailable.
Data Collection
The most significant limitation of using state cancer registry data to evaluate quality of care is that the AJCC staging scheme, also known as "TNM," is not required by CDC NPCR 10 . National cancer treatment guidelines, such as National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology™ (see http://www.nccn.org), recommend therapy based on TNM stage, which state cancer registries are not necessarily designed to collect. For the diagnosis years studied, Maine and New Hampshire required TNM staging to be reported, but Vermont did not.
In Vermont, the quality assurance process included validating previously reported TNM data, assigning TNM stage based on text in the registry, and deriving TNM from other staging variables reported.
Another limitation related to TNM stage is that the federal standards in cancer registration changed significantly from 2003 to 2004 (the two diagnosis years of the study). Data collection shifted from collecting the TNM stage group directly to deriving it from multiple data items via the Collaborative Stage Algorithm. In order to make the data from different years and different states comparable, we standardized the data items and values (i.e., "3B" is equivalent to "IIIB"). It is possible that changes in data collection over time and differences among the three states affect the stage distribution of the breast and colon cancers studied.
It may be difficult to tell whether differences in other measures, such as number of positive lymph nodes or whether chemotherapy was administered, are due to a true difference in disease burden or oncology care, versus an artifact of data collection. Major changes in cancer registration standards occur every three years, and minor changes occur every year. When multiple years of data are used and/or the data are older, the interpretation of findings becomes more complex. We attempted to improve data quality by contacting the reporting facilities when necessary to obtain better information from the medical record for missing or unknown staging and treatment data. This may not have completely compensated for data collection issues.
Cancer incidence data are at least 95 percent complete based on evaluation by the Centers for Disease Control and Prevention (CDC) and the North American Association of Central Cancer Registries (NAACCR). However, it is possible that people diagnosed with cancer were unreported by healthcare providers or healthcare facilities. It is also possible that Northern New England residents received their diagnosis and first course of treatment in a state that does not have an interstate data exchange agreement and, therefore, would not be reported to the central cancer registries.
Data Analysis
While the three states have interstate data exchange agreements that protect the confidentiality of data shared from one state providing a person's treatment to the other state where a person resides, there are no confidentiality agreements in place to share "same-state" records. For example, if a Vermont resident is treated by a Vermont healthcare facility; this record cannot be shared with the New Hampshire State Cancer Registry. The HIPAA safe harbor method for de-identifying records would have prohibited necessary data items from being shared among the three states. Therefore, we used a standardized method for each state to extract and aggregate data in a way that could be compared with the other states' data. This meant that we could not perform multivariate analyses and were unable to examine the effects of confounding variables in the aggregated data.
Discussion
The aim of this study was to evaluate whether differences in either stage at diagnosis or standard treatment occurred in rural versus urban areas. A total of 8,982 patient records were reviewed from three different demographic regions -small rural, large rural, and urban. This required the collaboration of physicians, nurses, and provider networks which compose the Northern New England Oncology Society (NNECOS), cancer registrars from 79 different hospitals in three states and their central registries, the three state cancer coalitions (Maine Cancer Consortium, Vermonters Taking Action Against Cancer, and New Hampshire Comprehensive Cancer Collaboration) and national organizations including the American Cancer Society, the Centers for Disease Control and Prevention, and the National Cancer Institute. The data collection process itself represented a unique opportunity to compare and streamline the various methodologies in these three states. Common definitions for rural (small rural and large rural) and urban areas helped to stratify patients into separate groups that could be assessed. The development of common data sets among the three states enabled us to evaluate a large cross section of patients. Data collection and data analysis were subject to certain limitations as described earlier. Despite these limitations the data set did show marked and expected consistency in biological markers such as histology for both breast and colon cancer, and estrogen and progesterone expression for breast cancer. Similar results in these biological characteristics across different demographic areas would underscore the fact that data collection is accurate, and the population being studied is relatively similar in the three demographic areas of these three states. The endpoints chosen in this study were felt to represent reasonable collectable data points representing cancer stage at diagnosis, and reasonable standard of care assumptions.
The breast cancer results show a higher percentage of younger women (<50 years old) diagnosed in urban areas (27.4%) compared to small rural areas (20.4%) and large rural areas (22.3%). More non invasive breast cancer was also diagnosed in urban areas (24.8%) than in large or small rural areas (19.1% and 19.0%, respectively). However, within the timeframe and scope of this study, we were unable to determine whether the non invasive disease occurred preferentially among younger women in urban areas. This could be addressed in future studies.
In contrast to the pattern seen for Stage 0, no increase in Stage I breast cancer was seen in urban areas. More patients presented with Stage I disease in small rural and large rural areas (40.7% and 44.1%) compared to urban areas (37.9%). If access to screening were substantially better in urban areas, we might have expected to see an increase in Stage 1 as well as Stage 0 breast cancer. Patients in both small rural and urban areas also had similar rates of Stage IV disease at diagnosis. The data suggest that, overall, there is no significant delay in diagnosis of breast cancer patients associated with rural residence in Northern New England.
We are unable to account directly for any differences in the patterns of use of screening mammography, which might underlie regional differences in Stage 0 cancers, but this is an area for future study. Collaboration with the Behavioral Risk Factor Surveillance System in each state, as well as the New Hampshire and Vermont mammography registries of the Breast Cancer Surveillance Consortium, could help further evaluate rural/urban access to breast cancer screening.
Breast conserving surgery was performed in similar proportions among rural and urban areas with 62.1% of women undergoing lumpectomy. The stage of disease and number of lymph nodes affected at the time of diagnosis were similar in the three geographic regions. However, greater proportions of women in urban areas had either sentinel lymph node sampling (SLN) or sentinel node sampling combined with regional node dissection. The data regarding utilization of sentinel node sampling alone was still maturing in 2002 and 2003, and several major centers were actively accruing patients to studies that answered the question of whether regional lymph node dissections needed to be done in patients who had sentinel lymph nodes sampled. The best way to interpret these data is to combine the sentinel alone and sentinel and regional lymph node dissection groups. The utilization of the combined sentinel lymph group (with and without regional lymph node dissection) was more common (44.1%) in urban areas than large rural (39.8%) and small rural areas (37.8%).
Access to radiation therapy after breast conserving surgery is an important standard component of care. Certain clinical situations may preclude the use of post operative radiation therapy. These would include co morbid conditions, small non invasive breast cancer, advanced age, proceeding to mastectomy, and previous radiation therapy. Only 48.0% of elderly patients (> 75 years of age) received radiation after lumpectomy therapy (compared to 77.9% patients less than 75 years of age).
Interestingly, there was a correlation between sentinel lymph node dissection and post lumpectomy radiation therapy. SLN patients received radiation therapy more frequently after lumpectomy than patients who underwent regional lymph node dissections without SLN (85.9% versus 75.5%). The SLN alone versus SLN with concurrent regional lymph node dissection groups showed no significant difference in frequency of radiation (85.9% versus 85.8%) in 1517 patients reviewed. The use of SLN was more common in urban (44.1%) than either large or small rural areas (39.9% and 37.6% respectively). However, the rates of post lumpectomy radiation therapy in small and large rural (70.9% and 73.9% respectively) versus urban areas (72.2%) showed no significant difference. Thus, the explanation for the higher use of radiation therapy in post lumpectomy patients undergoing some form of SLN procedure is not explained by geographical differences in this study. However, patients with access to a relatively new and developing modality such as SLN sampling did receive more radiation therapy. The reason why rates of radiation therapy frequency would be lower in lumpectomy patients who had regional lymph node dissection without SLN is an area which would require further study.
Radiation therapy was also delivered more frequently in the groups where there is a perceived benefit. Groups with larger tumors, more lymph nodes involved, and Stage III disease all received more frequent radiation therapy as expected.
Colon cancer patients evaluated in the three geographical areas also showed consistencies in certain characteristics. No significant difference was noted in the distribution of stage (Stage 0, I, II, III,IV) at presentation between rural and urban areas (p=0.666). Again, similar to the results from breast cancer, patients with early Stage I colon cancer were diagnosed at a similar frequency in small rural areas (26.0%) as in urban areas (23.2%). The histology of the different subgroups was also similar in the different geographical areas studied (p=0.805).
The proportion of patients with 12 or more lymph nodes removed was also similar in small rural (56.0%) and urban (56.9%) areas. Among patients that had any lymph nodes removed, there was a borderline significant difference in the proportions having 12 or more removed (versus any number fewer than 12) (p=0.079), when all three geographical areas were compared in these 1219 patients. The likelihood of having the standard 12 or more nodes removed was 56% in small rural, 50.6% large rural and 56.9% in urban areas. The total rate of 12 or more lymph nodes (versus fewer than 12 lymph nodes) sampled in Stage IIB and III colon cancer was 62.3% in patients receiving adjuvant chemotherapy and 60.3% in patients not receiving adjuvant chemotherapy. There was no statistically significant difference between these groups, which would suggest that the surgical resection defined by this standard was similar in small rural and urban areas.
The delivery of adjuvant therapy in Stage III colon cancer was less frequent in rural areas when compared to urban areas in this study and this finding was statistically significant. Patients in small rural and large rural areas received chemotherapy less often (58.3% and 55.8% respectively) than their urban counterparts (64.7% p<0.001). We tried to account for this observation in terms of potential confounding in the data. Age for instance is inversely associated with chemotherapy use but from Table 4 we see no significant differences in age or age distribution between geographical areas. We do not have information on co morbid conditions that might influence adjuvant chemotherapy use, and which potentially could vary by region. However, presumably those who are not able to receive chemotherapy because of poor performance status would likely not be able to undergo the surgery for the same reasons and so would be excluded from this analysis. Chemotherapy use may also be affected by whether this is the first primary at diagnosis -but again there was no geographical difference noted in Table 4 . Although we were not able to do multivariate analysis because we lack individual level data, we do not find anything obvious in our data to account for the geographical difference in adjuvant chemotherapy use. Certainly, the complexity, duration, cost, and travel for 6-12 months of adjuvant therapy could serve as a barrier to patients accessing this care. Since there is a significant overall survival advantage for adjuvant chemotherapy in Stage III colon cancer it would be important to determine why patients in rural areas received adjuvant chemotherapy less often than patients living in closer proximity to treatment (urban) areas (see Figure 1) .
Conclusions
The ability for a patient to access care in rural areas may be limited both by patient and network/provider considerations. Providing adequate care in rural areas requires coordinated planning and resource management to limit barriers to care in cancer patients. State boundaries do not serve as an isolated barrier but geographic differences may play a significant role. Thus, the Northern New England Clinical Oncology Society initiated this study to evaluate relevant data to establish whether there were differences in the delivery of oncologic care in small rural, large rural and urban areas of Vermont, New Hampshire, and Maine. This study is the first to actively coordinate data collection in three states to determine if there was a difference in care between rural and urban areas.
The infrastructure in place to deliver cancer care in northern New England is fragile, and the resources available to provide these services will be difficult to maintain. Thus, this coalition of partners was essential towards the success of this study. State epidemiologists, state cancer coalitions, physicians, and registrars worked seamlessly among the three states to overcome numerous hurdles. Intermediate endpoints such as those studied here merely enabled us to capture a glimpse of cancer care in northern New England in 2003 and 2004. These endpoints illustrate that similar cancer care is provided in rural and urban areas of northern New England. No evidence of stage migration was noted. Unlike Northeast Scotland, where a higher proportion of colon and lung cancer patients with advanced disease and diminished survival presented in rural areas 11 , patients in rural Northern New England presented with early stage invasive breast disease and colon cancer at a similar proportion to their urban counterparts.
This study also illustrated numerous other areas where the data were comparable in rural and urban areas of Northern New England such as the use of breast conserving surgery and proportion of any positive nodes. The utilization of post lumpectomy radiation therapy also did not differ in rural areas. The study did reveal differences between the care offered to urban patients over rural patients. Breast cancer patients in urban northern New England presented at a younger age and with a higher proportion of Stage 0 (i.e. non invasive disease). Additionally, patients undergoing sentinel lymph node sampling also received more post lumpectomy radiation than patients undergoing regional lymph node dissections, and colon cancer patients with Stage III disease proportionally received adjuvant chemotherapy less often in rural areas as opposed to their urban counterparts.
These differences may or may not result in overall survival differences but do point out that there are significant differences in care between rural and urban areas that should be studied further. If these disparities increase, or the fragile network in place is disrupted, then we would expect to see more glaring discrepancies than those noted here. The overriding goal of this study is to continue the collaboration established here so that we can prospectively collect data to measure these possible discrepancies. 
Northern New England
